PREDNISOLONE SODIUM PHOSPHATE | A040070 | BAUSCH AND LOMB INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from We Pharmaceuticals, Inc. FDA-1996-P-0316 We Pharmaceuticals, Inc. filed a suitability petition on December 13, 1996, requesting the FDA to determine that a 20.1mg Prednisolone Sodium Phosphate USP oral liquid formulation (15mg prednisolone base per 5ml) is suitable for an Abbreviated New Drug Application, as being similar and related to th | Other | 2017-05-04 | Open | We Pharmaceuticals |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.
Bausch and Lomb updated its corporate name from "BAUSCH AND LOMB" to "BAUSCH AND LOMB INC" for Prednisolone Sodium Phosphate (NDA 040070).
Old: BAUSCH AND LOMB
New: BAUSCH AND LOMB INC
Bausch and Lomb Pharmaceuticals Inc changed its legal entity name to Bausch and Lomb Inc for the prednisolone sodium phosphate NDA 040070.
Old: BAUSCH AND LOMB PHARMACEUTICALS INC
New: BAUSCH AND LOMB INC